Discover
IMVT
Immunovant, Inc.
36.95
2 x 27.09
2 x 47.28
bid
ask
-
0.70
1.86%
2 @ 07:30 PM
36.95 +0.00 (0.00%)
| Ytd | 45.36% | |
| 1y | 139.94% |
36.81
day range
38.17
14.78
52 week range
44.96
| Open | 37.97 | Prev Close | 37.65 | Low | 36.81 | High | 38.17 | Mkt Cap | 7.63B |
| Vol | 2.94M | Avg Vol | 1.21M | EPS | -2.81 | P/E | N/A | Forward P/E | -13.44 |
| Beta | 0.81 | Short Ratio | 14.06 | Inst. Own | 53.96% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-09 | 50-d Avg | 40.25 | 200-d Avg | 31.13 | 1yr Est | 48.88 |
| Income Statement | |||
| Operating Expenses | 160.32M | ||
| Research and Development Expense | 142.63M | ||
| Selling, General and Administrative Expense | 17.69M | ||
| Operating Income | -160.32M | ||
| Net Income | -153.22M | ||
| Net Income Common Stock | -153.22M | ||
| Net Income Common Stock (USD) | -153.22M | ||
| Consolidated Income | -153.22M | ||
| Earnings per Basic Share | -0.75 | ||
| Earnings per Basic Share (USD) | -0.75 | ||
| Earnings per Diluted Share | -0.75 | ||
| Earning Before Interest & Taxes (EBIT) | -153.22M | ||
| Earning Before Interest & Taxes (USD) | -153.22M | ||
| Weighted Average Shares | 205.55M | ||
| Weighted Average Shares Diluted | 205.55M | ||
| Balance Sheet | |||
| Cash and Equivalents | 797.80M | ||
| Cash and Equivalents (USD) | 797.80M | ||
| Trade and Non-Trade Receivables | 697.00K | ||
| Current Assets | 851.18M | ||
| Property, Plant & Equipment Net | 351.00K | ||
| Total Assets | 852.49M | ||
| Current Liabilities | 117.10M | ||
| Total Liabilities | 117.10M | ||
| Accumulated Retained Earnings (Deficit) | -1.90B | ||
| Accumulated Other Comprehensive Income | 725.00K | ||
| Shareholders Equity | 735.39M | ||
| Shareholders Equity (USD) | 735.39M | ||
| Assets Non-Current | 1.31M | ||
| Trade and Non-Trade Payables | 10.14M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 119.00K | ||
| Net Cash Flow from Financing | 20.10M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -104.31M | ||
| Issuance (Purchase) of Equity Shares | 20.10M | ||
| Net Cash Flow from Operations | -124.40M | ||
| Effect of Exchange Rate Changes on Cash | -4.00K | ||
| Share Based Compensation | 13.77M | ||